Afatinib Mediates Autophagic Degradation of ORAI1, STIM1, and SERCA2, Which Inhibits Proliferation of Non-Small Cell Lung Cancer Cells |
Kim, Mi Seong
(Department of Oral Physiology, Institute of Biomaterial-Implant, School of Dentistry, Wonkwang University)
Kim, So Hui (Department of Carbon Convergence Engineering, College of Engineering, Wonkwang University) Yang, Sei-Hoon (Department of Internal Medicine, School of Medicine, Wonkwang University) Kim, Min Seuk (Department of Oral Physiology, Institute of Biomaterial-Implant, School of Dentistry, Wonkwang University) |
1 | Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol 2020;61:167-79. DOI |
2 | Harvey RD, Adams VR, Beardslee T, Medina P. Afatinib for the treatment of EGFR mutation-positive NSCLC: a review of clinical findings. J Oncol Pharm Pract 2020;26:1461-74. DOI |
3 | Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003;4:517-29. DOI |
4 | Stewart TA, Yapa KT, Monteith GR. Altered calcium signaling in cancer cells. Biochim Biophys Acta 2015;1848:2502-11. DOI |
5 | Feng M, Grice DM, Faddy HM, Nguyen N, Leitch S, Wang Y, et al. Store-independent activation of Orai1 by SPCA2 in mammary tumors. Cell 2010;143:84-98. DOI |
6 | Roderick HL, Cook SJ. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer 2008;8:361-75. DOI |
7 | Deliot N, Constantin B. Plasma membrane calcium channels in cancer: Alterations and consequences for cell proliferation and migration. Biochim Biophys Acta 2015;1848:2512-22. DOI |
8 | Yang H, Zhang Q, He J, Lu W. Regulation of calcium signaling in lung cancer. J Thorac Dis 2010;2:52-6. |
9 | Chen YF, Lin PC, Yeh YM, Chen LH, Shen MR. Store-operated Ca(2+) entry in tumor progression: from molecular mechanisms to clinical implications. Cancers (Basel) 2019;11:899. DOI |
10 | Hoyer-Hansen M, Jaattela M. AMP-activated protein kinase: a universal regulator of autophagy? Autophagy 2007;3:381-3. DOI |
11 | Mulder C, Prust N, van Doorn S, Reinecke M, Kuster B, van Bergen En Henegouwen P, et al. Adaptive resistance to EGFR-targeted therapy by calcium signaling in NSCLC cells. Mol Cancer Res 2018;16:1773-84. DOI |
12 | Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 2012;11:2254-64. DOI |
13 | Sehgal P, Szalai P, Olesen C, Praetorius HA, Nissen P, Christensen SB, et al. Inhibition of the sarco/endoplasmic reticulum (ER) Ca(2+)-ATPase by thapsigargin analogs induces cell death via ER Ca(2+) depletion and the unfolded protein response. J Biol Chem 2017;292:19656-73. DOI |
14 | Derler I, Jardin I, Romanin C. Molecular mechanisms of STIM/Orai communication. Am J Physiol Cell Physiol 2016;310:C643-62. DOI |
15 | Krawczyk P, Kowalski DM, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Stencel K, et al. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of nonsmall cell lung cancer in patients with common and rare EGFR gene mutations. Oncol Lett 2017;13:4433-44. DOI |
16 | Mercer JC, Dehaven WI, Smyth JT, Wedel B, Boyles RR, Bird GS, et al. Large store-operated calcium selective currents due to co-expression of Orai1 or Orai2 with the intracellular calcium sensor, Stim1. J Biol Chem 2006;281:24979-90. DOI |
17 | Stella GM, Luisetti M, Inghilleri S, Cemmi F, Scabini R, Zorzetto M, et al. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. Respir Med 2012;106:173-83. DOI |
18 | Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 2013;6:135-43. |